JP2019529359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529359A5 JP2019529359A5 JP2019509467A JP2019509467A JP2019529359A5 JP 2019529359 A5 JP2019529359 A5 JP 2019529359A5 JP 2019509467 A JP2019509467 A JP 2019509467A JP 2019509467 A JP2019509467 A JP 2019509467A JP 2019529359 A5 JP2019529359 A5 JP 2019529359A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- disease
- disorders
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 230000000241 respiratory effect Effects 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000009079 Bronchial Spasm Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000012895 Gastric disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377219P | 2016-08-19 | 2016-08-19 | |
| US62/377,219 | 2016-08-19 | ||
| PCT/US2017/025609 WO2018034702A1 (en) | 2016-08-19 | 2017-03-31 | Beta-amino-isoquinolinyl amide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529359A JP2019529359A (ja) | 2019-10-17 |
| JP2019529359A5 true JP2019529359A5 (https=) | 2020-06-25 |
Family
ID=61191217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019509467A Pending JP2019529359A (ja) | 2016-08-19 | 2017-03-31 | ベータ−アミノ−イソキノリニルアミド化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9963432B2 (https=) |
| EP (1) | EP3500251A4 (https=) |
| JP (1) | JP2019529359A (https=) |
| KR (1) | KR20190039587A (https=) |
| CN (1) | CN109640971A (https=) |
| AU (1) | AU2017312712B2 (https=) |
| BR (1) | BR112019003232A2 (https=) |
| CA (1) | CA3033184C (https=) |
| MX (1) | MX2019002019A (https=) |
| WO (1) | WO2018034702A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| BR112020020008A2 (pt) * | 2018-03-30 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Sais mono ácido de 6-aminoisoquinolinas e seus usos |
| WO2020047496A1 (en) * | 2018-08-31 | 2020-03-05 | Aerie Pharmaceuticals, Inc. | Isoquinoline-steroid conjugates and uses thereof |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2021001713A1 (en) * | 2019-06-29 | 2021-01-07 | Micro Labs Limited | Process for the preparation of (s)-netarsudil, its salts & polymorphs |
| ES3015621T3 (en) * | 2019-12-31 | 2025-05-06 | Ind Tech Res Inst | Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and use of the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) * | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DK3811943T3 (da) * | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| US9643927B1 (en) * | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US10550087B2 (en) * | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
-
2017
- 2017-03-31 BR BR112019003232A patent/BR112019003232A2/pt not_active Application Discontinuation
- 2017-03-31 JP JP2019509467A patent/JP2019529359A/ja active Pending
- 2017-03-31 CN CN201780050718.3A patent/CN109640971A/zh active Pending
- 2017-03-31 CA CA3033184A patent/CA3033184C/en active Active
- 2017-03-31 EP EP17841778.8A patent/EP3500251A4/en not_active Withdrawn
- 2017-03-31 MX MX2019002019A patent/MX2019002019A/es unknown
- 2017-03-31 WO PCT/US2017/025609 patent/WO2018034702A1/en not_active Ceased
- 2017-03-31 KR KR1020197007986A patent/KR20190039587A/ko not_active Ceased
- 2017-03-31 AU AU2017312712A patent/AU2017312712B2/en not_active Ceased
- 2017-03-31 US US15/476,850 patent/US9963432B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529359A5 (https=) | ||
| RU2440330C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2013525458A5 (https=) | ||
| JP2019516766A5 (https=) | ||
| JP2021508686A5 (https=) | ||
| JP2021523221A5 (https=) | ||
| JP2019014758A5 (https=) | ||
| JP2011500550A5 (https=) | ||
| JP2020525429A5 (https=) | ||
| JP2014531441A5 (https=) | ||
| JP2011515397A5 (https=) | ||
| JP2013518050A5 (https=) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| RU2017122062A (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
| JP2013533253A5 (https=) | ||
| JP2011513410A5 (https=) | ||
| JP2009524691A5 (https=) | ||
| JP2015516420A5 (https=) | ||
| RU2015101032A (ru) | ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| RU2018101077A (ru) | Регуляторы nrf2 | |
| JP2012530705A5 (https=) | ||
| JP2015517574A5 (https=) | ||
| RU2010145459A (ru) | Ингибиторы активности протеинтирозинкиназы | |
| JP2016531126A5 (https=) |